Latest Breaking News On - Generation ventures - Page 1 : comparemela.com

Tessellate BIO Emerges from Stealth - Replimune Group (NASDAQ:REPL), NewAmsterdam Pharma (NASDAQ:NAMS)

The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populationsLead program targets Alternative Lengthening of Telomeres (ALT)

Noord hollandCity ofUnited kingdomRogier rooswinkelChris gardnerHilda pickettAndree blaukatSue charlesDaniela coutoEliot forsterClaus azzalinAndrew lightfootHead of oncology research at merck kgaChildren medical research instituteSynthetic lethalityAlternative lengthening

Tessellate BIO Emerges from Stealth

Tessellate BIO Emerges from Stealth
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Noord hollandUnited kingdomCity ofEliot forsterAndree blaukatClaus azzalinSue charlesAndrew lightfootChris gardnerDaniela coutoHilda pickettRogier rooswinkelChildren medical research instituteHead of oncology research at merck kgaSynthetic lethalityAlternative lengthening

Cognota closes $5 5-million USD Series A to make corporate LearnOps a thing

Toronto-based Cognota has secured $5.5 million USD in Series A funding to fuel the growth of its software for corporate learning and development teams.

Bryan austinNeal dempseyJay steinfeldSteve fredrickComerica bankFund partnersToronto based cognotaGeneral millsGrotech venturesGeneration venturesFeddev ontarioIdea fund partnersTyton partnersBdc capitalCeas investmentsCorporate learning and development

Mironid extends Series A round raising £35 million to date

Roche Venture Fund joins existing major investors Epidarex Capital, Sofinnova Partners and BioGeneration Ventures September 13, 2023: Glasgow, Scotland.

City ofUnited kingdomNoord hollandFrance generalGlasgow cityNeil wilkieDavid evansRoche venture fundScottish investment bankConsilium strategic communicationsUniversity of strathclydeEuropean investment fundEpidarex capitalSofinnova partnersAutosomal dominant polycystic kidney diseaseBiogeneration ventures

Mironid extends Series A round raising £35 million to date for development of first-in-class small molecules to treat life-threatening hereditary kidney disease

Mironid extends Series A round raising £35 million to date for development of first-in-class small molecules to treat life-threatening hereditary kidney disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomNoord hollandFrance generalGlasgow cityDavid evansNeil wilkieConsilium strategic communicationsRoche venture fundUniversity of strathclydeScottish investment bankEuropean investment fundEpidarex capitalSofinnova partnersAutosomal dominant polycystic kidney diseaseBiogeneration ventures